Why you should be investing in these ASX healthcare shares

While it may feel like the entire share market is in freefall, there are some ASX healthcare shares still delivering gains to shareholders.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

As the coronavirus crisis continues to escalate around the world, global equity markets are becoming increasingly volatile. Despite a promising rally late on Friday afternoon, the S&P/ASX 200 Index (ASX: XJO) suffered its worst single-day fall since 1987 on Monday, shedding a whopping 9.7%. This continues a horror slide for the index, which has lost over 30% of its value so far in 2020.

But if you're looking for something of a silver lining, at least not all areas of the market have been affected equally: the ASX health care index is only down 3.3% so far in 2020 at the time of writing.

This shows the benefits of diversifying into healthcare. This is a defensive sector, and one which will be actively engaged in the coming months in the fight against the spread of coronavirus both here and abroad.

If you're tired of watching the daily pendulum swings of your portfolio, here are 3 leading ASX healthcare shares that could help shield you from the worst of the current spate of market volatility.

CSL Limited (ASX: CSL)

ASX biotechnology company CSL specialises in the development of influenza vaccines and treatments for rare diseases. Despite recent selloffs in the market, CSL shareholders are still sitting on gains of 2% so far this year (at the time of writing) and might be forgiven for wondering what all the fuss is about.

While the development of a vaccine for the coronavirus is outside the scope of CSL's daily operations, the company did recently announce it was lending its expertise to the University of Queensland in their research into a potential vaccine.

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)

Fisher & Paykel Healthcare specialises in the treatment of respiratory illnesses including sleep apnoea. Remarkably, back in February, the New Zealand-based company announced that it had actually seen an increase in demand in China following the coronavirus outbreak. It upgraded its FY20 profit guidance from between NZ$255 million to NZ$265 million to a new range of NZ$260 million to NZ$270 million.

If you were just looking at a chart of the Fisher & Paykel Healthcare share price, you wouldn't believe we were currently suffering through our worst market crash since the crashes of 2008 or 1987. The company's share price has marched steadily upwards, even gaining 4% on Monday while the rest of the market nosedived. So far in 2020, Fisher and Paykel Healthcare is up close to 19% at the time of writing.

ResMed Inc (ASX: RMD)

Like Fisher & Paykel, ResMed specialises in the treatment of respiratory-related illnesses such as sleep apnoea and chronic obstructive pulmonary disease. Given that many of the most severe symptoms of coronavirus are respiratory, ResMed's medical devices may be employed in the fight against the disease. Its share price has also held up reasonably well so far this year, advancing a little over 2% to $22.39 as at the time of writing.

ResMed hasn't made an announcement to the market directly addressing the impacts of the coronavirus on its outlook for FY20. However, given the fact that Fisher & Paykel upgraded its profit guidance, perhaps ResMed may also see some revenue upside from the current crisis.

Rhys Brock has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A young man wearing glasses writes down his stock picks in his living room.
Opinions

2 amazing ASX shares I wish I'd bought earlier

I think these stocks are performing incredibly well.

Read more »

Person handing out $100 notes, symbolising ex-dividend date.
Share Market News

$20,000 invested in CBA and these ASX 200 shares 5 years ago is worth

Did these shares deliver the goods for investors? Let's find out.

Read more »

a business person checks his mobile phone outside a Wall Street office with an American flag and other business people in the background.
Share Market News

Is the 'sell America' trade back?

Institutional investors appear to be at odds with retail investors.

Read more »

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a disappointing end to a disappointing week for investors this Friday.

Read more »

Six smiling office colleagues stand in a row and look at the camera.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why ANZ, Clarity, IGO, and Pilbara Minerals shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Betr, Centuria Capital, GR Engineering, and Mach7 shares are pushing higher

These shares are having a good finish to the week. But why?

Read more »

woman holding 'hiring' sign in shop
Broker Notes

How much upside does Macquarie tip for Seek shares?

The broker recently reviewed Australian job ad volumes for May.

Read more »